Recent cancer therapies usually involve structure-based drug design process to accomplish early discovery phase.
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These modeling tools also used in the field of in silico ADMET prediction 6 including ligand-cytochrome P-450 (CYP450) interaction 7 and potential toxicity. In the structure-based or target-based drug discovery scheme, characterizing a ligand-protein interaction is the most important process affecting success rate to find lead compounds. There are numerous drug screening cases aided by structure-based approaches for various classes of diseases. 8, 9 The presence of structural information on the complex between ligand and target protein enhanced both drug design and hit finding capability in the drug development projects.
Protein kinase is a family of enzyme that phosphorylate other proteins by adding phosphate moiety to the protein. 10 The phosphorylation often causes conformational and thereby functional changes in the corresponding proteins.
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Protein kinases modulate cellular signal transduction pathways by the phosphorylation process in the course of cell proliferation or survival. 12, 13 This is critical event especially in the cancer cell developments; therefore, protein kinases are regarded as a reasonable drug target for cancer pharmaceuticals.
Phosphorylation works on the site basis; a single phosphoryl group derived from ATP molecule is mainly delivered onto the hydroxyl groups of Ser/Thr or Tyr residues in the substrate proteins.
14 The imidazole nitrogen of His or carboxyl oxygen of Asp is alternative phosphorylation sites by the kinases. 15 From the human genome sequencing, more than 500 protein kinases are predicted to exist, which is corresponding about 2% of entire eukaryotic genes. 13, 16 The most common form is Ser/Thr kinase, and followed by Tyr kinase. Epidermal growth factor receptor tyrosine kinase (EGFRK) is the characteristic enzyme to phosphorylate Tyr residue of substrate protein, which is affiliated with the Ras/ Raf mitogen-activated protein kinase (MAPK) signaling pathways. 17 A series of EGFRK inhibitors such as gefitinib (iressa, AstraZeneca) and erlotinib (tarceva, Genetech) has been developed as an anti-cancer agent including non-small cell lung cancer and colorectal cancer.
18,19 EGFR-positive cancer patients have shown an above 60% response rate for these drugs, but many of them develop resistance. 20 Novel drug candidates for the EGFRK have been being developed by the academia or industry to overcome resistance problems regarding commercial cancer drugs.
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Previous screening work to explore novel antagonists for the EGFRK has recently performed using by protein chip system in vitro. 22 Several lines of chemicals have shown remarkable inhibitory effects on the EGFRK from smallmolecular libraries in this preceding effort. 22 The present computational study has investigated molecular details of interactions between the EGFRK and the inhibitor, IPS-01002. Molecular docking and molecular dynamics simulations were conducted to trace structural characteristics of the EGFRK-inhibitor complex in silico. These two approaches have been usually combined to optimize drug-protein interaction during the drug discovery process. 23, 24 In this work, conformational features of inhibitor bound form of EGFRK were compared with the free form. A tyrphostin-51
25 was used as a positive control for the antagonist. A series of tyrphostins was known to inhibit biological activities 26 of general tyrosine kinases including EGFR.
27
Molecular structure of complex form of EGFRK with the inhibitor was obtained by docking simulation. The AutoDock program 28 was used to calculate docked pose structure of inhibitors upon EGFRK. Figure 1 is a snapshot of conformation for the kinase domain of EGFR and its complex structure bound to inhibitors. The EGFRK demonstrated typical ATP binding site between N-and C-terminal lobes. Both IPS-01002 and tyrphostin was docked into the ATP binding site of EGFRK. Thus they can be regarded as an ATP-competitive type of inhibitor for this kinase.
Molecular dynamics (MD) simulations were conducted using docked conformation of EGFRK-inhibitor complex to The radius of gyration (R G ) value of each EGFRK system was averaged to ca. 20 Å 2 during 5-ns of MD simulation time without significant differences among three EGFRK models (data not shown). Therefore global structural features of EFGRK during MD simulations were not changed by inhibitor binding on the protein.
The EGFRK have catalytic activity for phosphorylation of substrate by the ATP binding via conformational changes of activation loop (A-loop). 29 The A-loop characteristic does thereby act as a decisive point to influence phosphorylation reaction of the EGFR. In this process, the DFG motif at the A-loop coordinates important interaction between the EGFR and ATP molecule. 30 The conformation of this region is known to be largely changed by the action of inhibitors in the ATP-binding pocket of EGFR. 31 To ascertain major changes of EGFRK by binding of inhibitors, residue-byresidue RMSF values were analyzed during 5-ns of MD times. Figure 3 is an average backbone RMSF values for each amino acid residue of EGFRK, EGFRK-IPS01002, and EGFRK-tyrphostin complex. Meaningful reductions in RMSF values were observed for both inhibitor-bound EGFRK at the A-loop and substrate binding region. For the A-loop, the RMSF value of Ala840 in the MD simulation was 2.07 Å at free EGFRK. This value was decreased to 1.37 and 1.60 Å for EGFRK-IPS01002, and EGFRK-tyrphostin complex, respectively. The difference was also evident at the substrate binding region of the EGFR. The RMSF value of Phe886 was 3.52 Å, but the value was significantly declined to 1.95 and 1.56 Å for IPS-01002, and tyrphostin-bound EGFRK, respectively. Other regions of EGFRK did not reflect local changes significantly in RMSF values by inhibitor binding. It can be thereby concluded that the conformational changes of region adjacent to the A-loop of EGFR by ATP-binding may be potentially disturbed by the action of inhibitors. The IPS-01002 appears to stabilize the loop flexibility via strong molecular interactions in ATP binding site of EGFR.
Energetic aspects of EGFR-inhibitor binding were also analyzed with the simulation trajectories of EGFRK-IPS01002, and EGFRK-tyrphostin complex. Figure 4 is an interaction energy profile between inhibitors and each amino acid residue in EGFR from binding conformation of docked poses. Three residues in the EGFRK have shown distinctive energetic interactions with ISP-01002 or tyrphostin. These amino acids are Lys721, Glu738, Asp831, and they have characteristic positively or negatively charged residues. Tyrphostin made a strong interaction with positively charged Lys721 with -9.65 kcal/mol of intermolecular energy. The Lys721 in ATP-binding site of EGFR is considered a key residue to decide biological activity of the EGFR. In the previous studies, it was proposed that the single substitution of alanin 27 or methionine 32 for lysine at position 721 abolished the intrinsic kinase activity of the EGFR. By contrast, IPS-01002 Detailed energy changes during MD simulations by the reorganization of the complexes were summarized in the Table  1. The Table 1 gives information for the non-bonding intermolecular energy and solvation energy between inhibitors and whole EGFRK protein. For the interaction energy term, vdW attraction was predominant factor at the both IPS-01002 and tyrphostin compared with the electrostatic energy. Overall interaction energy was −35.01 and −54.45 kcal/mol for the EGFRK-IPS01002 and EGFRK-tyrphostin complex, respectively. Hereby molecular mechanic energies between inhibitors and EGFRK appear to be enough to maintain stable molecular complexes. For the solvation energy parameters, however, showed energy penalty in the both inhibitor-EGFRK complex. Therefore water solvation was not energetically favorable for this type of complexation. Entire binding energies composed of interaction and solvation energy terms were −28.43 and −7.48 kcal/mol for the EGFRK-IPS01002 and EGFRK-tyrphostin complex, respectively. Therefore IPS-01002 is more favorable antagonist for the EGFRK compared to the tryphostin based on the concept of binding free energy.
Comprehension for the molecular interaction between drug candidate and target protein requires detailed information on the 3D structure for the binding. In the present study, binding structures were obtained by molecular docking and dynamics simulations because there are no available crystal structures for the EGFRK complexed with IPS-01002 or tyrphostin. Both inhibitors made a strong complex with the EGFRK protein at ATP-competitive binding site, and they maintained stable molecular interactions during the MD simulations. Preferable binding of the IPS-01002 seems to make an Aloop of EGFRK stiffen, and this conformational feature drives the blocking action of inhibitor for a biological phosphorylation process by the EGFR. Detailed binding features between inhibitors and EGFRK were proposed as ligand-receptor interaction diagram in the supporting information (Fig. S1  and S2 ).
Computational Methods
Molecular Models and Molecular Docking Simulations. Initial three-dimensional structural model for the EGFR was taken from the Protein Data Bank (PDB id 1M17) as an inhibitor-bound form. Molecular models for the EGFR, IPS-01002, and typhostin were built using a Discovery Studio 3.1 Visualizer program (Accelrys Software Inc.). Flexible molecular docking jobs were performed by AutoDock 4.2 docking suite. 28 The AutoDock program is accurate and wellvalidated molecular docking tool in the field of computational drug discovery, in which global conformational searching is aided by finely designed local search algorithm.
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The affinity grid maps were constructed on the EGFRK structure in which the grid size was 70 × 70 × 70 Å with 0.370 Å of spacing. A Lamarckian Genetic Algorithm was used to perform global conformational searching with a maximum 4 × 10 6 energy evaluations and 200 individual populations. The Solis & Wets algorithm was coupled to the Lamarckian method in order to local searching using a maximum of 300 iterations per step. The IPS-01002 and tyrphostin chemicals were docked upon ATP-binding site of the EGFRK. The highest-scoring pose for each inhibitor with the EGFRK was ranked according to the AutoDock score.
Molecular Dynamics Simulations. Docked poses from previous molecular docking jobs were used as a starting conformation for the molecular dynamics calculation. The MD simulations were performed using a general molecular modeling program, CHARMM 35 35b1 with a parm22 allatom force field. Each EGFRK system was solvated with explicit TIP3P water 36 model. Water molecules were removed if they were closer than 2.8 Å to heavy atoms of the EGFRK protein. The molecular system was energy-minimized by 3,000 steps of conjugate gradient, followed by Adopted Basis Newton-Raphson until the root-mean-square gradient was less than 0.01 kcal/mol. The MD simulations were performed in the isothermal-isobaric ensemble at 300 K. Bond lengths of the molecules were constrained using a SHAKE 37 option to accept 2.0 fs of time step during the simulation. The long-range electrostatic interactions were treated using a particle mesh Ewald summation 38 method. The pressure and temperature of each EGFRK system was regulated by Langevin piston combined with Hoover's thermostat. 39 The system was gradually heated to targeted temper- 
